Sponsored Links
| Pharmos Announces Results Of Phase 2b Irritable Bowel Syndrome Study |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |||
|
Pharmos Corporation (Pink Sheets: PARS) announced the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome. Although the primary efficacy variable (% of weeks responding for adequate overall relief of IBS symptoms) did not reach statistical significance, the percentage responding for the Dextofisopam 200 mg group was higher than that observed for the Phase 2a trial. Read more: Irritable-Bowel Syndrome News From Medical News Today
|